Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study (2009)
- Authors:
- USP affiliated authors: HEGG, ROBERTO - FM ; MARANHAO, RAUL CAVALCANTE - FCF
- Unidades: FM; FCF
- DOI: 10.1007/s00280-008-0738-2
- Subjects: NANOPARTÍCULAS; EMULSÕES (FORMAS FARMACÊUTICAS); FARMACOCINÉTICA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Cancer Chemotherapy and Pharmacology
- ISSN: 0344-5704
- Volume/Número/Paginação/Ano: v. 63, n. 2, p. 281-287, 2009
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
PIRES, Luís Antonio et al. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemotherapy and Pharmacology, v. 63, n. 2, p. 281-287, 2009Tradução . . Disponível em: https://doi.org/10.1007/s00280-008-0738-2. Acesso em: 06 maio 2024. -
APA
Pires, L. A., Hegg, R., Valduga, C. J., Graziani, S. R., Rodrigues, D. G., & Maranhão, R. C. (2009). Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemotherapy and Pharmacology, 63( 2), 281-287. doi:10.1007/s00280-008-0738-2 -
NLM
Pires LA, Hegg R, Valduga CJ, Graziani SR, Rodrigues DG, Maranhão RC. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study [Internet]. Cancer Chemotherapy and Pharmacology. 2009 ; 63( 2): 281-287.[citado 2024 maio 06 ] Available from: https://doi.org/10.1007/s00280-008-0738-2 -
Vancouver
Pires LA, Hegg R, Valduga CJ, Graziani SR, Rodrigues DG, Maranhão RC. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study [Internet]. Cancer Chemotherapy and Pharmacology. 2009 ; 63( 2): 281-287.[citado 2024 maio 06 ] Available from: https://doi.org/10.1007/s00280-008-0738-2 - Transfer of lipids to HDL in patients with breast cancer
- One hour infusion of clodronate disodium for treating oncological pain due to bone metastases of solid tumors among adults
- One hour infusion of clodronate disodium for treating oncological pain due to bone metastases of solid tumors among adults
- Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide
- Avaliação de captação de uma emulsão lipídica semelhante a LDL em carcinoma de mama
- Use of cholesterol-rich microemulsion that binds to low-density lipotein (LDL) receptors as avehicle for etoposide
- A lipidic microemulsion that binds to LDL receptors abolishes the side effects of high doses of a chemotherapeutic agent
- Uptake of a cholesterol-rich emulsion by breast cancer
- Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemotherapy
- Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemothrapy
Informações sobre o DOI: 10.1007/s00280-008-0738-2 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
